QI
CRL icon

QS Investors’s Charles River Laboratories CRL Stock Holding History

QS Investors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$616K Buy
1,664
+550
+49% +$184K 0.01% 656
2021
Q1 		$323K Hold
1,114
– – ﹤0.01% 960
2020
Q4 		$278K Buy
1,114
+114
+11% +$27.1K ﹤0.01% 1019
2020
Q3 		$227K Hold
1,000
– – ﹤0.01% 1035
2020
Q2 		$175K Sell
1,000
-600
-38% -$95.8K ﹤0.01% 1171
2020
Q1 		$202K Hold
1,600
– – ﹤0.01% 1064
2019
Q4 		$247K Hold
1,600
– – ﹤0.01% 1139
2019
Q3 		$212K Hold
1,600
– – ﹤0.01% 1192
2019
Q2 		$228K Hold
1,600
– – ﹤0.01% 1186
2019
Q1 		$233K Sell
1,600
-12
-0.7% -$1.58K ﹤0.01% 1168
2018
Q4 		$183K Sell
1,612
-44,959
-97% -$5.63M ﹤0.01% 1153
2018
Q3 		$6.27M Sell
46,571
-248
-0.5% -$30.6K 0.06% 212
2018
Q2 		$5.26M Sell
46,819
-119
-0.3% -$12.9K 0.05% 269
2018
Q1 		$5.01M Sell
46,938
-91
-0.2% -$9.81K 0.05% 263
2017
Q4 		$5.15M Sell
47,029
-2,947
-6% -$321K 0.05% 286
2017
Q3 		$5.4M Sell
49,976
-4,256
-8% -$437K 0.04% 281
2017
Q2 		$5.49M Sell
54,232
-1,006
-2% -$92.6K 0.05% 276
2017
Q1 		$4.97M Sell
55,238
-41,167
-43% -$3.5M 0.04% 294
2016
Q4 		$7.34M Sell
96,405
-31,019
-24% -$2.36M 0.06% 232
2016
Q3 		$10.6M Sell
127,424
-47,791
-27% -$4.01M 0.08% 194
2016
Q2 		$14.4M Sell
175,215
-9,409
-5% -$775K 0.12% 147
2016
Q1 		$14M Buy
184,624
+66,987
+57% +$4.96M 0.13% 140
2015
Q4 		$9.46M Buy
117,637
+2,655
+2% +$191K 0.09% 195
2015
Q3 		$7.3M Buy
114,982
+26,358
+30% +$1.89M 0.08% 240
2015
Q2 		$6.23M Sell
88,624
-69,631
-44% -$5.15M 0.08% 312
2015
Q1 		$12.5M Sell
158,255
-21,542
-12% -$1.59M 0.14% 163
2014
Q4 		$11.4M Buy
+179,797
New +$11.3M 0.13% 179
2014
Q2 		– Sell
-3,500
Closed -$211K – 788
2014
Q1 		$211K Buy
+3,500
New +$204K 0.01% 579

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

QS Investors's CRL Position: Q2 2021 in Review

QS Investors increased its Charles River Laboratories (CRL) stake by 49% in Q2 2021, buying an estimated $184K and bringing the position to 1,664 shares worth $616K. The position accounts for 0.01% of the portfolio, ranked #656.

QS Investors first reported a position in CRL in Q1 2014 and has held it in 28 quarters since. The position peaked at $14.4M in Q2 2016. 639 funds tracked by Wall St. Rank hold CRL as of Q2 2021.

  • QS Investors held 1,664 shares of Charles River Laboratories worth $616K as of Q2 2021.
  • QS Investors bought 550 Charles River Laboratories shares in Q2 2021, an estimated $184K.
  • Charles River Laboratories made up 0.01% of QS Investors's portfolio in Q2 2021, its #656 holding.
  • QS Investors first reported a position in Charles River Laboratories in Q1 2014 and has held it in 28 quarters since.
  • QS Investors's Charles River Laboratories position peaked at $14.4M in Q2 2016.
  • 639 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.